Baidu
map

Tissue Eng Regen Med:人眼轮匝肌肌源性干细胞的体外和体内成骨

2019-01-09 MedSci MedSci原创

治疗骨缺损的细胞的疗法需要具有成骨潜力的干细胞来源。肌肉的病理性骨化表明人体骨骼肌含有成骨祖细胞。然而,肌肉样本通常通过创伤性活组织检查程序获得,该程序引起供体的疼痛和发病。在这里,我们确定了一种新的骨骼肌干细胞替代来源(SMSCs),而不会给捐赠者带来并发症。使用两步电镀方法获得从人眼轮匝肌(OOM)片段分离的贴壁细胞,其目前在眼科整容手术期间丢弃。分别评估细胞生长动力学,免疫表型和体外多谱系分

治疗骨缺损的细胞的疗法需要具有成骨潜力的干细胞来源。肌肉的病理性骨化表明人体骨骼肌含有成骨祖细胞。然而,肌肉样本通常通过创伤性活组织检查程序获得,该程序引起供体的疼痛和发病。在这里,我们确定了一种新的骨骼肌干细胞替代来源(SMSCs),而不会给捐赠者带来并发症。

使用两步电镀方法获得从人眼轮匝肌(OOM)片段分离的贴壁细胞,其目前在眼科整容手术期间丢弃。分别评估细胞生长动力学,免疫表型和体外多谱系分化能力。此外,用GFP基因转导成骨诱导的细胞,加载到多孔β-磷酸三钙(β-TCP)生物陶瓷上,并移植到无胸腺小鼠的皮下部位。评估异位骨形成并检测体内细胞转化。

结果现实,OOM衍生的细胞在形状上是成纤维细胞,在生长中克隆形成,并且显示出与SMSCs类似的表型和行为特征。特别地,这些细胞可以通过细胞外基质钙化和增强的碱性磷酸酶(ALP)活性和骨钙素(OCN)产生在体外诱导成成骨细胞。在植入后6周,在载有细胞的生物陶瓷中发现了新的骨形成。通过使用GFP标记技术,检测到这些肌细胞参与体内异位成骨过程。

综上所述,这些数据表明,人类OOM组织是骨祖细胞用于骨修复和再生的有价值且无创的资源。

原始出处:

Liu G, Liao C, Chen X, Wu Y. In Vitro and In Vivo Osteogenesis of Human Orbicularis Oculi Muscle-Derived Stem Cells. Tissue Eng Regen Med. 2018 May 29;15(4):445-452. doi: 10.1007/s13770-018-0122-1. eCollection 2018 Aug.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1911368, encodeId=e20219113684c, content=<a href='/topic/show?id=df471e4882e' target=_blank style='color:#2F92EE;'>#Tissue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17488, encryptionId=df471e4882e, topicName=Tissue)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu May 16 07:13:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081517, encodeId=6457208151ef4, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 12 07:13:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351951, encodeId=6acd1351951dd, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 10 17:13:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609466, encodeId=bcaf160946676, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 10 17:13:00 CST 2019, time=2019-01-10, status=1, ipAttribution=)]
    2019-05-16 xuyu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1911368, encodeId=e20219113684c, content=<a href='/topic/show?id=df471e4882e' target=_blank style='color:#2F92EE;'>#Tissue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17488, encryptionId=df471e4882e, topicName=Tissue)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu May 16 07:13:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081517, encodeId=6457208151ef4, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 12 07:13:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351951, encodeId=6acd1351951dd, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 10 17:13:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609466, encodeId=bcaf160946676, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 10 17:13:00 CST 2019, time=2019-01-10, status=1, ipAttribution=)]
    2019-01-12 spoonycyy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1911368, encodeId=e20219113684c, content=<a href='/topic/show?id=df471e4882e' target=_blank style='color:#2F92EE;'>#Tissue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17488, encryptionId=df471e4882e, topicName=Tissue)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu May 16 07:13:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081517, encodeId=6457208151ef4, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 12 07:13:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351951, encodeId=6acd1351951dd, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 10 17:13:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609466, encodeId=bcaf160946676, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 10 17:13:00 CST 2019, time=2019-01-10, status=1, ipAttribution=)]
    2019-01-10 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1911368, encodeId=e20219113684c, content=<a href='/topic/show?id=df471e4882e' target=_blank style='color:#2F92EE;'>#Tissue#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17488, encryptionId=df471e4882e, topicName=Tissue)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu May 16 07:13:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081517, encodeId=6457208151ef4, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Jan 12 07:13:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351951, encodeId=6acd1351951dd, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jan 10 17:13:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609466, encodeId=bcaf160946676, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 10 17:13:00 CST 2019, time=2019-01-10, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map